PCM
FLNA

Poehling Capital Management’s Filana Therapeutics FLNA Stock Holding History

Poehling Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,000
Closed -$7K – 324
2018
Q1 		$7K Buy
+1,000
New +$6.75K 0.01% 254

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Poehling Capital Management's FLNA Position: Q2 2018 in Review

Poehling Capital Management sold out of Filana Therapeutics (FLNA) in Q2 2018, closing a stake of 1,000 shares — an estimated $7K sold.

Poehling Capital Management first reported a position in FLNA in Q1 2018 and held it in 1 quarter. The position peaked at $7K in Q1 2018. 24 funds tracked by Wall St. Rank hold FLNA as of Q2 2018.

  • Poehling Capital Management reported no remaining Filana Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Poehling Capital Management sold 1,000 Filana Therapeutics shares in Q2 2018, an estimated $7K.
  • Poehling Capital Management first reported a position in Filana Therapeutics in Q1 2018 and held it in 1 quarter.
  • Poehling Capital Management's Filana Therapeutics position peaked at $7K in Q1 2018.
  • 24 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2018.

Based on Poehling Capital Management's 13F filing for Q2 2018, filed 8 Aug 2018.